The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Large-scale comparative analysis of clinico-genomic characteristics, treatment outcomes and resistant mechanisms of ALK/ROS1/RET-rearranged non-small cell lung cancer (NSCLC) in a nationwide genomic screening project (LC-SCRUM-Asia/TRY).
 
Yosuke Kagawa
No Relationships to Disclose
 
Yuji Shibata
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Merck; Ono Pharmaceutical; Pfizer; Takeda
Research Funding - Blueprint Medicines (Inst); Chugai Pharma (Inst); MSD (Inst); Novartis (Inst)
 
Shingo Matsumoto
Honoraria - Amgen; AstraZeneca; Chugai Pharma; Guardant Health; Lilly; Merck; Novartis; Riken; Thermo Fisher Scientific
Research Funding - Chugai Pharma (Inst); Janssen (Inst); Merck (Inst); MSD (Inst); Novartis (Inst)
 
Hiroki Izumi
Honoraria - Bristol-Myers Squibb Japan; Chugai/Roche; Merck; MSD; Ono Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen
Research Funding - Amgen (Inst); AstraZeneca (Inst); Eisai/MSD (Inst); Ono Pharmaceutical (Inst); Takeda (Inst)
 
Yuichiro Ohe
Honoraria - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Celltrion; Chugai Pharma; Eisai; Kyowa Hakko Kirin; Lilly Japan; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen; Anheart Therapeutics; AstraZeneca; Celltrion; Chugai Pharma; Kyorin; Lilly Japan; Novartis; Ono Pharmaceutical; Takeda
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Janssen (Inst); Lilly Japan (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Ryo Toyozawa
Honoraria - AstraZeneca; Chugai Pharma; Lilly Japan; MSD; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Abbvie (Inst); Amgen (Inst); AnHeart Therapeutics (Inst); Daiichi Sankyo (Inst); Lilly Japan (Inst); Novartis (Inst); Pfizer (Inst); Takeda (Inst)
 
Kazumi Nishino
Honoraria - AstraZeneca Japan; Bristol-Myers Squibb Japan; Chugai Pharma; Janssen; Lilly Japan; Merck; Nippon Boehringer Ingelheim; Nippon Kayaku; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Lilly Japan; Pfizer
Research Funding - Abbvie (Inst); Amgen (Inst); Chugai Pharma (Inst); Daiichi Sankyo/UCB Japan (Inst); Eisai (Inst); Janssen (Inst); Lilly Japan (Inst); Merck (Inst); Merus (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Atsushi Nakamura
Honoraria - AstraZeneca; Chugai Pharma; Kyowa Kirin; Lilly Japan; MSD; Novartis; Taiho Pharmaceutical; Thermo Fisher Scientific
 
Kadoaki Ohashi
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Kyowa-Kirin; Lilly; MSD; Nippon Kayaku; Novartis
Research Funding - AstraZeneca/MedImmune; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Lilly
 
Shoichi Kuyama
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo Pharmaceutical; Hisamitsu Pharmaceutical; Kyowa Kirin; Lilly O.; MSD; Pfizer; Taiho Pharmaceutical; Takeda; Tsumura & Co.
 
Naoki Furuya
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly; Novartis; Pfizer; Taiho Pharmaceutical
 
Tetsuya Sakai
Honoraria - AstraZeneca; Chugai Pharma; Merck; MSD; Novartis; Thermo Fisher Scientific
Research Funding - Amgen
 
Kaname Nosaki
Honoraria - AstraZeneca; Chugai Pharma; Janssen; Lilly; Merck; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Abbvie; Daiichi Sankyo/UCB Japan
Research Funding - Abbvie (Inst); Anheart Therapeutics (Inst); AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo/UCB Japan (Inst); MSD K.K (Inst); Takeda (Inst)
 
Hibiki Udagawa
Honoraria - AstraZeneca
Research Funding - Boehringer Ingelheim; Takeda
 
Shigeki Umemura
Honoraria - Chugai Pharma
 
Yoshitaka Zenke
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Lilly; MSD Oncology; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - AstraZeneca (Inst); Merck Serono (Inst); MSD (Inst)
 
Kiyotaka Yoh
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Janssen; Kirin Pharmaceuticals; Lilly Japan; Novartis; Taiho Pharmaceutical
Consulting or Advisory Role - Boehringer Ingelheim
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Lilly Japan (Inst); MSD (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Koichi Goto
Honoraria - Amgen; Amgen; Amoy Diagnostics; AstraZeneca Japan; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb K.K.; Chugai Pharma; DAIICHI SANKYO Co., Ltd.; Eisai; Guardant Health; Janssen; Life Technologies; Lilly Japan; Medpace; Merck; Novartis; Ono Pharmaceutical; Otsuka; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen; Bayer; Janssen; Lilly Japan; Medpace
Research Funding - Amgen (Inst); Amgen (Inst); Amgen Astellas BioPharma (Inst); AstraZeneca Japan (Inst); Bayer Yakuhin (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb K.K. (Inst); Chugai Pharma (Inst); DAIICHI SANKYO Co., Ltd. (Inst); Eisai (Inst); Ignyta (Inst); Janssen (Inst); Kissei Pharmaceutical (Inst); Kyowa Kirin Co., Ltd. (Inst); Lilly Japan (Inst); Loxo (Inst); MEDICAL & BIOLOGICAL LABORATORIES CO., LTD. (Inst); Merck (Inst); Merus (Inst); MSD K.K. (Inst); NEC Corporation (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Shanghai HaiHe Pharmaceutical (Inst); Spectrum Pharmaceuticals (Inst); Sumitomo Dainippon Pharma Co., Ltd. (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Thermo Fisher Scientific (Inst); Turning Point Therapeutics (Inst)